Author Correction: In vitro characterization of immune modulating drug-eluting immunobeads towards transarterial embolization in cancer

Ayele H. Negussie, Andrew S. Mikhail, Joshua Owen, Natalie Hong, Camella J. Carlson, Yiqing Tang, Kendal P. Carrow, Michal Mauda‐Havakuk, Andrew L. Lewis, John W. Karanian, William F. Pritchard, Bradford J. WoodScientific 2023 · DOI · OpenAlex

Introduction

This article provides a formal correction to the study "In vitro characterization of immune modulating drug-eluting immunobeads towards transarterial embolization in cancer," originally published in Scientific Reports in December 2022. The research focuses on the development and characterization of DC Bead LUMI, a specialized microsphere designed for transarterial embolization (TAE). This procedure aims to treat cancer by simultaneously obstructing the blood supply to tumors and delivering high local concentrations of therapeutic agents.

Nature of the Correction

Following publication, errors were identified in the reported drug-loading capacities for several immune-modulating compounds. These inaccuracies appeared in both the Abstract and Table 2 of the original manuscript. Accurate drug-loading data is fundamental for calculating therapeutic windows and ensuring the safety and efficacy of dosage delivery in clinical settings.

Updated Loading Capacities

The primary correction involves the maximum drug loading for BMS-202. The original Table 2 incorrectly reported a loading capacity of $147.19 \pm 2.19$ mg/ml.

The original, incorrect loading value for BMS-202 in Table 2.

The validated maximum loading capacity for BMS-202 is $148.05 \pm 2.24$ mg of drug per milliliter of beads.

The corrected loading value for BMS-202 in Table 2.

Abstract Realignment

In addition to the numerical correction for BMS-202, the sequence of drug-loading values in the Abstract was realigned to correctly match the respective compounds. The definitive maximum drug loading values for the DC Bead LUMI platform are as follows:

  • Dox: $204.54 \pm 3.87$ mg/ml
  • GARD: $65.97 \pm 1.54$ mg/ml (previously misaligned as $65.28 \pm 3.09$)
  • DSR 6434: $65.95 \pm 6.96$ mg/ml
  • IMQ: $65.28 \pm 3.09$ mg/ml (previously misaligned as $65.97 \pm 1.54$)
  • BMS-202: $148.05 \pm 2.24$ mg/ml

Conclusion

While the numerical adjustments are specific, they are critical for maintaining the scientific rigor of the study. These corrections ensure that the loading capacities for immune-modulating drugs on DC Bead LUMI are accurately represented for future research and potential clinical translation.

Summary updated

Abstract

Maximum drug loading was 204.54 3.87, 65.28 3.09, 65.95 6.96, 65.97 1.54, and 148.05 2.24 mg of drug per milliliter of DC Bead LUMI for Dox, GARD, DSR 6434, IMQ, and BMS-202, respectively." now reads: "Maximum drug loading was 204.54 3.87, 65.97 1.54, 65.95 6.96, 65.28 3.09, and 148.05 2.24 mg of drug per milliliter of DC Bead LUMI for Dox, GARD, DSR 6434, IMQ, and BMS-202, respectively."The original version of this Article also contained an error in Table 2, where the "Maximum drug loaded, mg drug/ml beads" value was incorrect for "BMS-202".The incorrect and correct value appears below.
BibTeX
@inproceedings{negussie2023author,
  author = {Ayele H. Negussie and Andrew S. Mikhail and Joshua Owen and Natalie Hong and Camella J. Carlson and Yiqing Tang and Kendal P. Carrow and Michal Mauda‐Havakuk and Andrew L. Lewis and John W. Karanian and William F. Pritchard and Bradford J. Wood},
  title = {{Author Correction: In vitro characterization of immune modulating drug-eluting immunobeads towards transarterial embolization in cancer}},
  booktitle = {Scientific},
  year = {2023},
  doi = {10.1038/s41598-023-30659-z},
}
Figure